Find insights on China’s healthcare sector, Thomson Medical Group, Cochlear, and more in the latest Market Talks covering the ...

Study Forecasts 7.0% CAGR, with the CDMO Market Expanding from $136.6 Billion in 2024 to $191.6 Billion by 2029, Fueled by Increased Demand for Outsourced Drug Development and Manufacturing.Boston, ...

Leading the thin upside was Hansoh Pharmaceutical, gaining 0.7%, while Wuxi AppTec declined 8.1% ... the Australian ASX 200 inclined 0.4%; the Singapore Straits Times Index rose 0.5%, and the ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. The deal includes facilities in ...

WuXi AppTec Co, Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene ...

Contract research organisation (CRO) NAMSA has acquired the US-based medical device testing operations of WuXi AppTec to strengthen its medtech clinical research testing capabilities. The deal ...

Chinese contract drug maker WuXi AppTec rose 7.0% in afternoon trade in Hong Kong, on track for its largest daily percentage gain since early December. Its sister company WuXi Biologics rose 4.7% ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Wuxi AppTec and more, was excluded from the National Defense Authorization Act (NDAA) for fiscal year 2025 that was put forth for Senate approval in early December. The BIOSECURE act was expected ...